Revenue scaled more than twofold over the ten-quarter window while gross margin held near 84% (83.9% in 2026Q3), yet operating margin fell from 47.6% in 2025Q3 to 35.3% in 2026Q3, indicating operating income is growing more slowly than revenue.
Eli Lilly and Company (LLY) annual income statement — 30-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Sales/Revenue | 86.46B | 65.18B | 45.04B | 34.12B | 28.54B | 28.32B | 24.54B | 22.32B | 21.49B | 19.97B | 21.22B | 19.96B | 19.62B | 23.11B | 22.6B | 24.29B | 23.08B | 21.84B | 20.37B | 18.63B | 15.69B | 14.65B | 13.86B | 12.58B | 11.08B | 11.54B | 10.86B | 10B | 9.24B | 7.99B | 7B |
| Revenue Growth % | 45.51% | 44.7% | 32% | 19.56% | 0.79% | 15.4% | 9.95% | 3.84% | 7.61% | -5.88% | 6.33% | 1.75% | -15.13% | 2.25% | -6.93% | 5.25% | 5.68% | 7.19% | 9.33% | 18.75% | 7.14% | 5.68% | 10.14% | 13.59% | -4.03% | 6.26% | 8.59% | 8.29% | 15.64% | 14.14% | 3.47% |
| Cost of Goods Sold | 14.15B | 11.05B | 8.42B | 7.08B | 6.63B | 7.31B | 5.48B | 4.72B | 4.68B | 4.45B | 5.71B | 5.04B | 4.93B | 4.91B | 4.8B | 5.07B | 4.37B | 4.25B | 4.38B | 4.25B | 3.55B | 3.47B | 3.22B | 2.68B | 2.18B | 2.16B | 1.62B | 1.66B | 1.52B | 1.44B | 1.33B |
| COGS % of Revenue | - | 16.96% | 18.69% | 20.75% | 23.23% | 25.82% | 22.34% | 21.15% | 21.78% | 22.27% | 26.91% | 25.24% | 25.15% | 21.24% | 21.22% | 20.87% | 18.92% | 19.45% | 21.48% | 22.8% | 22.6% | 23.72% | 23.26% | 21.26% | 19.65% | 18.72% | 14.91% | 16.58% | 16.51% | 17.98% | 18.98% |
| Gross Profit | 72.31B | 54.13B | 36.63B | 27.04B | 21.91B | 21.01B | 19.06B | 17.6B | 16.81B | 15.53B | 15.51B | 14.92B | 14.68B | 18.2B | 17.81B | 19.22B | 18.71B | 17.59B | 16B | 14.38B | 12.14B | 11.17B | 10.63B | 9.91B | 8.9B | 9.38B | 9.24B | 8.34B | 7.71B | 6.55B | 5.67B |
| Gross Margin % | 83.63% | 83.04% | 81.31% | 79.25% | 76.77% | 74.18% | 77.66% | 78.85% | 78.22% | 77.73% | 73.09% | 74.76% | 74.85% | 78.76% | 78.78% | 79.13% | 81.08% | 80.55% | 78.52% | 77.2% | 77.4% | 76.28% | 76.74% | 78.74% | 80.35% | 81.28% | 85.09% | 83.42% | 83.49% | 82.02% | 81.02% |
| Gross Profit Growth % | - | 47.79% | 35.44% | 23.41% | 4.31% | 10.23% | 8.29% | 4.68% | 8.28% | 0.09% | 3.96% | 1.62% | -19.35% | 2.24% | -7.35% | 2.72% | 6.37% | 9.96% | 11.2% | 18.45% | 8.71% | 5.05% | 7.33% | 11.31% | -5.13% | 1.51% | 10.76% | 8.2% | 17.71% | 15.55% | 4.38% |
| Operating Expenses | 32.48B | 24.43B | 19.59B | 16.25B | 13.26B | 13.07B | 11.85B | 11.6B | 10.79B | 11.28B | 11.64B | 11.33B | 11.35B | 12.66B | 12.79B | 12.9B | 11.94B | 11.22B | 10.47B | 9.58B | 8.02B | 7.52B | 6.98B | 6.41B | 5.57B | 5.65B | 5.68B | 4.98B | 4.89B | 4.11B | 3.63B |
| OpEx % of Revenue | - | 37.48% | 43.48% | 47.63% | 46.45% | 46.16% | 48.27% | 51.97% | 50.18% | 56.46% | 54.85% | 56.76% | 57.88% | 54.76% | 56.59% | 53.12% | 51.73% | 51.38% | 51.38% | 51.42% | 51.11% | 51.36% | 50.33% | 50.91% | 50.31% | 48.97% | 52.32% | 49.79% | 52.91% | 51.49% | 51.8% |
| Selling, General & Admin | 12.62B | 11.09B | 8.59B | 6.94B | 6.07B | 6.14B | 5.87B | 6B | 5.73B | 6.18B | 6.33B | 6.53B | 6.62B | 7.13B | 7.51B | 7.88B | 7.05B | 6.89B | 6.63B | 6.1B | 4.89B | 4.5B | 4.28B | 4.06B | 3.42B | 3.42B | 3.23B | 2.76B | 2.66B | 2.23B | 1.89B |
| SG&A % of Revenue | - | 17.02% | 19.08% | 20.34% | 21.26% | 21.69% | 23.92% | 26.9% | 26.68% | 30.94% | 29.83% | 32.73% | 33.75% | 30.83% | 33.24% | 32.45% | 30.57% | 31.56% | 32.53% | 32.71% | 31.16% | 30.71% | 30.92% | 32.23% | 30.91% | 29.61% | 29.72% | 27.57% | 28.78% | 27.96% | 27.04% |
| Research & Development | 15.38B | 13.34B | 10.99B | 9.31B | 7.19B | 6.93B | 5.98B | 5.59B | 5.05B | 5.1B | 5.31B | 4.8B | 4.73B | 5.53B | 5.28B | 5.02B | 4.88B | 4.33B | 3.84B | 3.49B | 3.13B | 3.03B | 2.69B | 2.35B | 2.15B | 2.24B | 2.02B | 1.78B | 1.74B | 1.37B | 1.19B |
| R&D % of Revenue | - | 20.46% | 24.4% | 27.29% | 25.19% | 24.47% | 24.35% | 25.07% | 23.5% | 25.51% | 25.02% | 24.03% | 24.13% | 23.93% | 23.35% | 20.67% | 21.17% | 19.81% | 18.85% | 18.71% | 19.94% | 20.66% | 19.42% | 18.68% | 19.4% | 19.36% | 18.58% | 17.83% | 18.83% | 17.15% | 17% |
| Other Operating Expenses | 1000K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 435.8M | 439.7M | 490.4M | 509.8M | 543.5M |
| Operating Income | 39.83B | 29.7B | 17.04B | 10.79B | 8.65B | 7.93B | 7.21B | 6B | 6.03B | 4.25B | 3.87B | 3.59B | 3.33B | 5.55B | 5.02B | 6.32B | 6.77B | 6.37B | 5.53B | 4.8B | 4.13B | 3.65B | 3.66B | 3.5B | 3.33B | 3.73B | 3.56B | 3.36B | 2.82B | 2.44B | 2.04B |
| Operating Margin % | 46.07% | 45.56% | 37.83% | 31.61% | 30.32% | 28.01% | 29.38% | 26.88% | 28.04% | 21.28% | 18.24% | 18% | 16.97% | 24% | 22.19% | 26.01% | 29.35% | 29.17% | 27.13% | 25.78% | 26.29% | 24.91% | 26.4% | 27.83% | 30.04% | 32.31% | 32.77% | 33.63% | 30.58% | 30.53% | 29.21% |
| Operating Income Growth % | - | 74.27% | 57.96% | 24.66% | 9.08% | 10.02% | 20.19% | -0.44% | 41.79% | 9.78% | 7.77% | 7.91% | -40% | 10.62% | -20.62% | -6.71% | 6.31% | 15.23% | 15.1% | 16.42% | 13.07% | -0.28% | 4.48% | 5.23% | -10.78% | 4.78% | 5.83% | 19.09% | 15.83% | 19.28% | 3.15% |
| EBITDA | 42B | 31.69B | 18.81B | 12.31B | 10.18B | 9.48B | 8.53B | 7.23B | 7.63B | 5.82B | 5.37B | 5.02B | 4.71B | 6.99B | 6.48B | 7.69B | 8.1B | 7.67B | 6.65B | 5.85B | 4.93B | 4.38B | 4.26B | 4.05B | 3.82B | 4.18B | 4B | 3.8B | 3.31B | 2.95B | 2.59B |
| EBITDA Margin % | 48.58% | 48.62% | 41.75% | 36.09% | 35.65% | 33.48% | 34.78% | 32.4% | 35.52% | 29.12% | 25.29% | 25.15% | 24% | 30.26% | 28.66% | 31.67% | 35.1% | 35.12% | 32.65% | 31.4% | 31.4% | 29.87% | 30.71% | 32.19% | 34.49% | 36.25% | 36.78% | 38.02% | 35.89% | 36.91% | 36.98% |
| EBITDA Growth % | 48.49% | 68.52% | 52.72% | 21.02% | 7.33% | 11.08% | 18.01% | -5.28% | 31.25% | 8.37% | 6.93% | 6.63% | -32.69% | 7.97% | -15.78% | -5.05% | 5.64% | 15.3% | 13.67% | 18.74% | 12.62% | 2.79% | 5.08% | 6.01% | -8.7% | 4.74% | 5.05% | 14.74% | 12.44% | 13.93% | 2.06% |
| D&A (Non-Cash Add-back) | 2.17B | 2B | 1.77B | 1.53B | 1.52B | 1.55B | 1.32B | 1.23B | 1.61B | 1.57B | 1.5B | 1.43B | 1.38B | 1.45B | 1.46B | 1.37B | 1.33B | 1.3B | 1.12B | 1.05B | 801.8M | 726.4M | 597.5M | 548.5M | 493M | 454.9M | 435.8M | 439.7M | 490.4M | 509.8M | 543.5M |
| EBIT | 42.58B | 29.7B | 17.04B | 7.04B | 7.14B | 6.5B | 7.59B | 5.67B | 3.92B | 2.53B | 3.56B | 2.95B | 3.15B | 6.05B | 5.59B | 5.54B | 6.71B | 5.62B | -1.08B | 4.8B | 4.13B | 3.65B | 3.66B | 3.5B | 3.33B | 3.73B | 3.56B | 3.36B | 2.82B | 2.44B | 2.04B |
| Net Interest Income | -1.18B | -642M | -605.4M | -312.3M | -268.8M | -314.4M | -326.6M | -320.2M | -83.2M | -58.6M | -76.5M | -74.2M | -27.8M | -40.4M | -72.8M | -106.1M | -133.6M | -186.1M | -17.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 153.3M | 175.2M | 173.6M | 62.8M | 25.4M | 33M | 80.4M | 159.3M | 166.4M | 108.7M | 87M | 121M | 119.7M | 105M | 79.9M | 51.9M | 75.2M | 210.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.18B | 795.3M | 780.6M | 485.9M | 331.6M | 339.8M | 359.6M | 400.6M | 242.5M | 225M | 185.2M | 161.2M | 148.8M | 160.1M | 177.8M | 186M | 185.5M | 261.3M | 228.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -5.06B | -3.96B | -4.36B | -4.23B | -1.85B | -1.78B | 19.1M | -733.5M | -2.35B | -1.95B | -497.3M | -802.1M | -328.4M | 341.2M | 392.9M | -968.4M | -247M | -1.01B | -6.84B | -926.1M | -707.4M | -931.1M | -716.8M | -240.1M | 130M | -177.7M | 299M | -118.3M | -159.5M | 462.7M | 87M |
| Pretax Income | 34.77B | 25.73B | 12.68B | 6.55B | 6.81B | 6.16B | 7.23B | 5.27B | 3.68B | 2.3B | 3.37B | 2.79B | 3B | 5.89B | 5.41B | 5.35B | 6.53B | 5.36B | -1.31B | 3.88B | 3.42B | 2.72B | 2.94B | 3.26B | 3.46B | 3.55B | 3.86B | 3.25B | 2.67B | 2.9B | 2.13B |
| Pretax Margin % | 40.21% | 39.48% | 28.15% | 19.21% | 23.85% | 21.74% | 29.46% | 23.59% | 17.12% | 11.54% | 15.9% | 13.98% | 15.3% | 25.48% | 23.93% | 22.03% | 28.28% | 24.54% | -6.42% | 20.81% | 21.78% | 18.56% | 21.23% | 25.92% | 31.21% | 30.77% | 35.52% | 32.44% | 28.85% | 36.32% | 30.45% |
| Income Tax | 7.19B | 5.09B | 2.09B | 1.31B | 561.6M | 573.8M | 1.04B | 628M | 529.5M | 2.39B | 636.4M | 381.6M | 609.8M | 1.2B | 1.32B | 1B | 1.46B | 1.03B | 764.3M | 923.8M | 755.3M | 715.9M | 1.13B | 700.9M | 749.8M | 742.7M | 800.9M | 698.7M | 568.7M | 885.2M | 505.6M |
| Effective Tax Rate % | 20.68% | 19.79% | 16.48% | 20.05% | 8.25% | 9.32% | 14.33% | 11.93% | 14.39% | 103.75% | 18.86% | 13.68% | 20.32% | 20.45% | 24.4% | 18.73% | 22.31% | 19.21% | -58.45% | 23.83% | 22.1% | 26.34% | 38.47% | 21.49% | 21.68% | 20.91% | 20.76% | 21.53% | 21.34% | 30.51% | 23.72% |
| Net Income | 27.58B | 20.64B | 10.59B | 5.24B | 6.24B | 5.58B | 6.19B | 8.32B | 3.23B | -204.1M | 2.74B | 2.41B | 2.39B | 4.68B | 4.09B | 4.35B | 5.07B | 4.33B | -2.07B | 2.95B | 2.66B | 1.98B | 1.81B | 2.56B | 2.71B | 2.78B | 3.06B | 2.72B | 2.1B | -385.1M | 1.52B |
| Net Margin % | 31.9% | 31.67% | 23.51% | 15.36% | 21.88% | 19.71% | 25.24% | 37.27% | 15.04% | -1.02% | 12.9% | 12.07% | 12.19% | 20.27% | 18.09% | 17.9% | 21.97% | 19.82% | -10.17% | 15.85% | 16.97% | 13.52% | 13.06% | 20.35% | 24.45% | 24.08% | 28.15% | 27.2% | 22.71% | -4.82% | 21.77% |
| Net Income Growth % | 49.79% | 94.9% | 102.08% | -16.08% | 11.88% | -9.88% | -25.54% | 157.38% | 1683.54% | -107.46% | 13.67% | 0.75% | -48.97% | 14.58% | -5.96% | -14.24% | 17.11% | 308.93% | -170.16% | 10.9% | 34.51% | 9.36% | -29.32% | -5.43% | -2.59% | -9.09% | 12.38% | 29.7% | 644.77% | -125.28% | -33.5% |
| Net Income (Continuing) | 27.58B | 20.64B | 10.59B | 5.24B | 6.24B | 5.58B | 6.19B | 4.64B | 3.15B | -86.4M | 2.74B | 2.41B | 2.39B | 4.68B | 4.09B | 4.35B | 5.07B | 4.33B | -2.07B | 2.95B | 2.66B | 2B | 1.81B | 2.56B | 2.71B | 2.81B | 3.06B | 2.55B | 2.1B | 2.02B | 1.63B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.68B | 81.4M | -117.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 174.3M | 8.8M | -2.4B | -102.2M |
| Minority Interest | 0 | 0 | 79.5M | 91.8M | 125.6M | 175.6M | 183.6M | 92.2M | 1.08B | 75.7M | 72.8M | 19M | 14.9M | 9.3M | 8.7M | -6.1M | -7.5M | 1.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 160M | 0 |
| EPS (Diluted) | 30.87 | 22.95 | 11.71 | 5.80 | 6.57 | 5.85 | 6.47 | 8.69 | 3.13 | -0.19 | 2.49 | 2.18 | 2.15 | 4.19 | 3.57 | 3.90 | 4.58 | 3.94 | -1.89 | 2.71 | 2.45 | 1.81 | 1.66 | 2.37 | 2.50 | 2.55 | 2.79 | 2.46 | 1.87 | -0.34 | 1.36 |
| EPS Growth % | 50.73% | 95.99% | 101.9% | -11.72% | 12.31% | -9.58% | -25.55% | 177.64% | 1747.37% | -107.63% | 14.22% | 1.4% | -48.69% | 17.37% | -8.46% | -14.85% | 16.24% | 308.47% | -169.74% | 10.61% | 35.36% | 9.04% | -29.96% | -5.2% | -1.96% | -8.6% | 13.41% | 31.55% | 650% | -125% | -32.67% |
| EPS (Basic) | - | 23.07 | 11.76 | 5.83 | 6.57 | 5.85 | 6.47 | 8.69 | 3.14 | -0.19 | 2.49 | 2.18 | 2.15 | 4.19 | 3.57 | 3.90 | 4.58 | 3.94 | -1.89 | 2.71 | 2.45 | 1.82 | 1.67 | 2.38 | 2.51 | 2.58 | 2.83 | 2.50 | 1.91 | -0.35 | 1.39 |
| Diluted Shares Outstanding | 893.4M | 898M | 904.06M | 903.28M | 950.18M | 953.65M | 956.59M | 957.53M | 1.03B | 1.05B | 1.1B | 1.11B | 1.11B | 1.12B | 1.15B | 1.11B | 1.11B | 1.1B | 1.09B | 1.09B | 1.09B | 1.09B | 1.09B | 1.08B | 1.08B | 1.09B | 1.1B | 1.11B | 1.12B | 1.13B | 1.12B |
| Basic Shares Outstanding | 891.9M | 898M | 900.61M | 899.38M | 950.18M | 953.65M | 956.59M | 957.53M | 1.03B | 1.05B | 1.1B | 1.11B | 1.11B | 1.12B | 1.15B | 1.11B | 1.11B | 1.1B | 1.09B | 1.09B | 1.09B | 1.09B | 1.08B | 1.08B | 1.08B | 1.08B | 1.08B | 1.09B | 1.1B | 1.1B | 1.09B |
| Dividend Payout Ratio | - | 26.09% | 44.2% | 77.65% | 56.62% | 55.3% | 43.38% | 28.97% | 71.53% | - | 78.85% | 88.33% | 87.9% | 45.27% | 53.5% | 50.14% | 42.71% | 49.72% | - | 62.77% | 65.21% | 83.6% | 85.07% | 56.35% | 49.33% | 43.42% | 36.82% | 36.77% | 41.84% | - | 49.44% |
Quick answers to the most common questions about buying LLY stock.
For fiscal year 2025, Eli Lilly and Company (LLY) reported total revenue of $65.18B. This represents a 831.4% increase compared to $7.00B in 1996.
Eli Lilly and Company (LLY) is profitable, generating $20.64B in net income for the fiscal year ending 2025 with a net profit margin of 31.7%.
Eli Lilly and Company (LLY) reported an operating income of $29.70B, resulting in an operating profit margin of 45.6%. This margin reflects the operational efficiency of the business before interest and taxes.
Eli Lilly and Company (LLY) generated $54.13B in gross profit for the year, representing a gross profit margin of 83.0%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Incretin franchise concentration risk
Metrics are mathematically derived from official filings.
Top-Line Growth Re-Accelerated Sharply Then Moderated
According to reported quarterly figures, LLY's revenue rose from $11.3B in 2024Q2 to $24.4B in 2026Q3, with year-over-year growth peaking near 55.5% in 2026Q1 before easing to 38.6% in the latest quarter.
The sequence of growth rates suggests the expansion is being driven largely by the metabolic franchise, consistent with tirzepatide adoption, rather than broad-based portfolio strength. The decline from the 2026Q1 peak implies incremental gains are moderating against a substantially larger base. Investors should monitor whether growth holds as supply constraints ease and competitive pressure from Novo Nordisk intensifies.
Gross Margin Anchored Near 84 Percent
As reported in the income statement history, LLY's gross margin has held between 80.8% and 85.8% across the last ten quarters, with the latest quarter at 83.9%, consistent with a high-value, patent-protected product mix.
Stability of gross margin across rapidly rising volumes suggests pricing power and limited unit-cost pressure from manufacturing scale-up. The modest dip in the most recent quarter may reflect higher production or channel costs during capacity build-out rather than a change in pricing. Gross-to-net dynamics are not fully visible in this data, so margin durability should be checked against future rebate disclosures.
Operating Leverage Has Compressed Recently
Based on LLY's reported figures, operating margin expanded from 39.1% in 2024Q2 to a peak of 47.6% in 2025Q3 before easing to 35.3% in 2026Q3, meaning operating income grew more slowly than revenue in the most recent quarters.
The pattern indicates that R&D and SG&A have grown faster than gross profit in the latest periods, with R&D reaching $4.2B and SG&A $3.1B in 2026Q3. This may reflect deliberate reinvestment in pipeline and commercial launches rather than a loss of efficiency. Whether margins recover depends on whether the spending step-up proves temporary or becomes a permanent cost base.
Margin Compression Could Persist Under Pricing Pressure
Based on reported figures, LLY's operating margin has fallen roughly 12 points from its 2025Q3 peak of 47.6% to 35.3% in 2026Q3, a trajectory that could continue if pricing or payer dynamics tighten further.
The bear case centers on whether the recent decline reflects a structural shift in pricing rather than temporary spending timing. Sustained revenue growth paired with shrinking margins would suggest that volume gains are coming at higher rebate or discount cost, which warrants further investigation. If R&D and SG&A keep rising at current rates, the earnings base could become more sensitive to any slowdown in tirzepatide demand.
Net Income Volatility Warrants Scrutiny
Based on reported figures, LLY's net margin ranged from 8.5% in 2024Q3 to 37.4% in 2026Q1, and diluted EPS of $7.22 in 2026Q3 sits below the 2026Q1 level of $8.26, suggesting non-operating items or tax effects are influencing bottom-line results.
Operating margins remained above 35 percent throughout, so the large swings in net margin point to below-the-line items rather than core operating performance. Stock-based compensation of roughly $140M to $200M per quarter does not appear to explain the variance. Earnings quality would be better assessed once the drivers of these non-operating movements, including collaboration milestones, are isolated.